Biocon is currently trading at Rs. 423.85, up by 9.25 points or 2.23% from its previous closing of Rs. 414.60 on the BSE.

The scrip opened at Rs. 423.00 and has touched a high and low of Rs. 428.60 and Rs. 417.50 respectively. So far 144958 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 455.00 on 13-Jul-2020 and a 52 week low of Rs. 211.30 on 20-Aug-2019.

Last one week high and low of the scrip stood at Rs. 455.00 and Rs. 396.00 respectively. The current market cap of the company is Rs. 49752.00 crore.

The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 23.11% and 16.21% respectively.

Biocon has received the Drugs Controller General of India’s (DCGI) approval to market Itolizumab (ALZUMAb) Injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19.

Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications. Biocon has repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody launched in India in 2013 as ALZUMAb for treating chronic plaque psoriasis, for the treatment of CRS in moderate to severe ARDS patients due to COVID-19. Itolizumab will be manufactured and formulated as an intravenous injection at Biocon’s bio-manufacturing facility at Biocon Park, Bengaluru.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient’s worldwide.